8-K Announcements
6Material company update
Feb 23, 2026·SEC
Material company update
Dec 31, 2025·SEC
Material company update
Nov 18, 2025·SEC
Avenue Therapeutics, Inc.(ATXI)Earnings, Financials & Key Ratios
ATXI•NASDAQ
Price updated Jun 19, 2026
AboutAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.Show more
- Revenue$1M
- EBITDA-$3M+71.9%
- Net Income-$3M+75.0%
- EPS (Diluted)-0.93-3.3%
- Gross Margin100%
- EBITDA Margin-234.05%
- Operating Margin-234.05%
- Net Margin-207.19%
- ROE-157.75%+83.0%
ATXI Key Insights
Avenue Therapeutics, Inc. (ATXI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 75.8% through buybacks
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 17 (bottom 17%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ATXI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATXI Price & Volume
Avenue Therapeutics, Inc. (ATXI) stock price & volume — 10-year historical chart
Loading chart...
ATXI Growth Metrics
Avenue Therapeutics, Inc. (ATXI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM87.17%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM88.04%
Return on Capital
10 Years-395.43%
5 Years-437.45%
3 Years-606.36%
Last Year-178.2%
ATXI Recent Earnings
Avenue Therapeutics, Inc. (ATXI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (50%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.21+99.6%
$56.25
Rev
—
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.22+99.6%
$56.25
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.21
—
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.11
—
Rev
$1M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.21vs $56.25+99.6% | — |
| Q2 2026 | Mar 30, 2026 | $0.22vs $56.25+99.6% | — |
| Q4 2025 | Nov 13, 2025 | $0.21 | — |
| Q3 2025 | Aug 14, 2025 | $0.11 | $1M |
Based on last 12 quarters of dataView full earnings history →
ATXI Peer Comparison
Avenue Therapeutics, Inc. (ATXI) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 COLL | 1.09B | 33.54 | 19.39 | 23.62% | 9.41% | 26.74% | 3.12 | |
 MNKD | 1.22B | 3.94 | 197 | 22.23% | -6.63% | |||
 XTLB | 279.46K | 2.54 | -0.26 | -227.72% | -25.53% | 0.03 | ||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 MCK | 90.23B | 750.63 | 19.56 | 12.36% | 1.18% |
Compare ATXI vs Peers
Avenue Therapeutics, Inc. (ATXI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATXI Income Statement
Avenue Therapeutics, Inc. (ATXI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.4M | 1.4M |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 1.4M▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | 100% | 0% |
Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
Operating Expenses | 6.7M | 21.82M | 26.27M | 5.21M | 3.74M | 8.04M | 14.54M | 11.28M | 4.69M | 3.5M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | 334.05% | - |
Selling, General & Admin | 3.62M | 4.12M | 3.07M | 2.35M | 2.48M | 5.34M | 4.18M | 4.64M | 3.65M | 2.67M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | 260.19% | - |
Research & Development | 7.8M | 17.7M | 23.19M | 2.87M | 1.25M | 2.7M | 10.36M | 6.64M | 1.04M | 826K |
R&D % of Revenue | - | - | - | - | - | - | - | - | 73.86% | - |
Other Operating Expenses | -99K | 175K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -11.42M▲ 0% | -21.82M▼ 91.0% | -26.27M▼ 20.4% | -5.21M▲ 80.2% | -3.74M▲ 28.3% | -8.04M▼ 115.2% | -14.54M▼ 80.8% | -11.28M▲ 22.4% | -3.29M▲ 70.9% | -2.1M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | -234.05% | -149.29% |
Operating Income Growth % | -380.48% | -91.02% | -20.39% | 80.15% | 28.29% | -115.17% | -80.78% | 22.4% | 70.88% | - |
EBITDA | 0 | 0 | -25.91M | -5.15M | 0 | -2.44M | 0 | -11.7M | -3.29M | -2.06M |
EBITDA Margin % | - | - | - | - | - | - | - | - | -234.05% | -146.37% |
EBITDA Growth % | - | - | - | 80.12% | 100% | - | 100% | - | 71.9% | 77.79% |
D&A (Non-Cash Add-back) | 11.42M | 21.82M | 0 | 0 | 3.74M | 0 | 14.54M | 0 | 0 | 0 |
EBIT | -11.88M | -21.55M | -25.91M | -5.15M | -3.73M | -2.44M | -10.49M | -11.7M | -3.29M | -2.06M |
Net Interest Income | -287K | 0 | 357K | 62K | 7K | -1.14M | 126K | 176K | 121K | 107K |
Interest Income | 88K | 93K | 357K | 62K | 7K | 20K | 126K | 176K | 121K | 107K |
Interest Expense | 375K | 0 | 0 | 0 | 0 | 1.16M | 0 | 0 | 0 | 0 |
Other Income/Expense | -837K | 268K | 357K | 62K | 7K | 4.44M | 4.05M | -413K | 339K | 311K |
Pretax Income | -12.26M▲ 0% | -21.55M▼ 75.8% | -25.91M▼ 20.2% | -5.15M▲ 80.1% | -3.73M▲ 27.6% | -3.6M▲ 3.4% | -10.49M▼ 191.1% | -11.7M▼ 11.5% | -2.95M▲ 74.8% | -1.78M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | -209.9% | -127.07% |
Income Tax | 0 | -268K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 1.24% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -12.26M▲ 0% | -21.55M▼ 75.8% | -25.91M▼ 20.2% | -5.15M▲ 80.1% | -3.73M▲ 27.6% | -3.55M▲ 4.8% | -10.38M▼ 192.1% | -11.65M▼ 12.3% | -2.91M▲ 75.0% | -1.75M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | -207.19% | -124.79% |
Net Income Growth % | -285.84% | -75.79% | -20.23% | 80.12% | 27.57% | 4.8% | -192.15% | -12.29% | 75.03% | 87.17% |
Net Income (Continuing) | -12.26M | -21.55M | -25.91M | -5.15M | -3.73M | -3.6M | -10.49M | -11.7M | -2.95M | -1.77M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | -639K | -928K | -941K | 0 | 0 |
EPS (Diluted) | -27.71▲ 0% | -31.17▼ 12.5% | -24.38▲ 21.8% | -4.65▲ 80.9% | -3.29▲ 29.2% | -121.91▼ 3605.5% | -73.48▲ 39.7% | -0.90▲ 98.8% | -0.93▼ 3.3% | -0.53▲ 0% |
EPS Growth % | -414.1% | -12.49% | 21.78% | 80.93% | 29.25% | -3605.47% | 39.73% | 98.78% | -3.33% | 88.04% |
EPS (Basic) | -27.71 | -31.17 | -24.38 | -4.65 | -3.29 | -121.91 | -73.60 | -0.90 | -0.93 | - |
Diluted Shares Outstanding | 442.33K | 682.61K | 1.05M | 1.1M | 1.13M | 29.14K | 141.22K | 12.95M | 3.13M | 3.29M |
Basic Shares Outstanding | 442.33K | 682.61K | 1.05M | 1.1M | 1.13M | 29.14K | 141K | 12.95M | 3.13M | 3.29M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ATXI Balance Sheet
Avenue Therapeutics, Inc. (ATXI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 22.17M | 4.53M | 8.91M | 3.25M | 3.96M | 6.84M | 1.85M | 2.67M | 2.85M | 2.42M |
Cash & Short-Term Investments | 21.78M | 2.67M | 8.74M | 3.13M | 3.76M | 6.71M | 1.78M | 2.59M | 2.85M | 2.42M |
Cash Only | 11.78M | 2.67M | 8.74M | 3.13M | 3.76M | 6.71M | 1.78M | 2.59M | 2.85M | 2.42M |
Short-Term Investments | 10M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 90K | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 51.99 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 1.7M | 0 | 0 | 0 | 0 | 0 | 78K | 0 | 0 |
Total Non-Current Assets | 0 | 1.85M | 170K | 113K | 0 | 0 | 67K | 0 | 0 | 0 |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 1.85M | 170K | 113K | 0 | 0 | 67K | 0 | 0 | 0 |
Total Assets | 22.17M▲ 0% | 4.53M▼ 79.6% | 8.91M▲ 97.0% | 3.25M▼ 63.6% | 3.96M▲ 22.0% | 6.84M▲ 72.9% | 1.85M▼ 73.0% | 2.67M▲ 44.4% | 2.93M▲ 9.7% | 2.47M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.48x | 0.42x |
Asset Growth % | 11153.81% | -79.59% | 97.02% | -63.6% | 22.03% | 72.85% | -72.97% | 44.43% | 9.69% | 3.69% |
Total Current Liabilities | 2.79M | 5.16M | 2.12M | 886K | 509K | 3.58M | 1.2M | 816K | 1.1M | 1.27M |
Accounts Payable | 1.54M | 3.09M | 354K | 172K | 304K | 150K | 401K | 155K | 0 | 0 |
Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 1M | 0 | 24K | 2.61M | 784K | 34K | 1.1M | 1.27M |
Current Ratio | 7.95x | 0.88x | 4.22x | 3.66x | 7.78x | 1.91x | 1.55x | 3.27x | 2.60x | 1.90x |
Quick Ratio | 7.95x | 0.88x | 4.22x | 3.66x | 7.78x | 1.91x | 1.55x | 3.27x | 2.60x | 1.90x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 51.99 |
Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 2.79M | 5.16M | 2.12M | 886K | 509K | 3.58M | 1.2M | 816K | 1.1M | 1.27M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net Debt | -11.78M | -2.67M | -8.74M | -3.13M | -3.76M | -6.71M | -1.78M | -2.59M | -2.85M | -2.42M |
Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.18x |
Interest Coverage | -31.69x | - | - | - | - | -2.11x | - | - | - | - |
Total Equity | 19.38M▲ 0% | -631K▼ 103.3% | 6.8M▲ 1177.7% | 2.36M▼ 65.3% | 3.45M▲ 46.3% | 3.27M▼ 5.4% | 654K▼ 80.0% | 1.86M▲ 183.8% | 1.83M▼ 1.3% | 1.2M▲ 0% |
Equity Growth % | 334.97% | -103.26% | 1177.65% | -65.31% | 46.29% | -5.36% | -79.98% | 183.79% | -1.29% | -36.51% |
Book Value per Share | 43.81 | -0.92 | 6.49 | 2.14 | 3.05 | 112.10 | 4.63 | 0.14 | 0.59 | 0.36 |
Total Shareholders' Equity | 19.38M | -631K | 6.8M | 2.36M | 3.45M | 3.9M | 1.58M | 2.8M | 1.83M | 1.2M |
Common Stock | 1K | 1K | 2K | 2K | 0 | 0 | 3K | 0 | 0 | 0 |
Retained Earnings | -20.66M | -42.21M | -68.12M | -73.27M | -77M | -80.55M | -90.93M | -102.58M | -105.49M | -106.18M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 1.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | -639K | -928K | -941K | 0 | 0 |
ATXI Cash Flow Statement
Avenue Therapeutics, Inc. (ATXI) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.8M | -18.22M | -26.26M | -4.61M | -3.75M | -7.6M | -9.45M | -9.03M | -1.83M | -1.08M |
Operating CF Margin % | - | - | - | - | - | - | - | - | -130.56% | - |
Operating CF Growth % | -316.79% | -167.8% | -44.15% | 82.43% | 18.71% | -102.56% | -24.42% | 4.5% | 79.69% | 256.73% |
Net Income | -12.26M | -21.55M | -25.91M | -5.15M | -3.73M | -3.6M | -10.38M | -11.7M | -2.91M | -1.75M |
Depreciation & Amortization | 174K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 604K | 1.54M | 1.84M | 710K | 442K | 649K | 906K | 1.24M | 665K | 541K |
Deferred Taxes | 277K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.32M | 412K | 61K | 0 | 0 | -5.05M | 310K | 1.25M | 111K | 833K |
Working Capital Changes | 2.08M | 1.79M | -2.25M | -172K | -461K | 408K | -290K | 179K | 300K | -675K |
Change in Receivables | 0 | 0 | 0 | 0 | -90K | 90K | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 2.23M | 1.13M | -3.23M | -229K | 0 | 0 | -360K | 0 | 298K | -437K |
Cash from Investing | -10M | 10M | 0 | -1M | 0 | 0 | -3M | 0 | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | -1M | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -10K | -10M | 0 | 0 | 0 | 0 | -3M | 0 | 0 | 0 |
Cash from Financing | 28.39M | -895K | 32.33M | 0 | 4.38M | 10.54M | 7.53M | 9.84M | 2.09M | 0 |
Debt Issued (Net) | -3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 37.95M | 0 | 35M | 0 | 5.04M | 10.39M | 7.53M | 1.62M | 2.09M | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -1.1M | 0 | 0 | 0 | 0 |
Other Financing | -6.56M | -895K | -2.67M | 0 | -663K | 148K | 1K | 8.21M | 0 | 0 |
Net Change in Cash | 11.59M▲ 0% | -9.11M▼ 178.6% | 6.07M▲ 166.7% | -5.61M▼ 192.4% | 631K▲ 111.2% | 2.94M▲ 366.7% | -4.92M▼ 267.2% | 811K▲ 116.5% | 261K▼ 67.8% | -1.08M▲ 0% |
Free Cash Flow | -6.8M▲ 0% | -18.22M▼ 167.8% | -26.26M▼ 44.2% | -5.61M▲ 78.6% | -3.75M▲ 33.2% | -7.6M▼ 102.6% | -12.45M▼ 63.9% | -9.03M▲ 27.5% | -1.83M▲ 79.7% | -1.08M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | -130.56% | -77.28% |
FCF Growth % | -316.79% | -167.8% | -44.15% | 78.62% | 33.19% | -102.56% | -63.92% | 27.51% | 79.69% | 84.7% |
FCF per Share | -15.38 | -26.69 | -25.06 | -5.10 | -3.31 | -260.72 | -88.17 | -0.70 | -0.59 | -0.33 |
FCF Conversion (FCF/Net Income) | 0.55x | 0.85x | 1.01x | 0.90x | 1.01x | 2.14x | 0.91x | 0.77x | 0.63x | 0.62x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATXI Key Ratios
Avenue Therapeutics, Inc. (ATXI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -220.23% | -229.86% | -839.94% | -112.48% | -128.43% | -105.76% | -529.44% | -928.45% | -157.75% | -85.83% |
Return on Invested Capital (ROIC) | -340.79% | -761.73% | - | - | - | - | - | - | - | 151.81% |
Gross Margin | - | - | - | - | - | - | - | - | 100% | 0% |
Net Margin | - | - | - | - | - | - | - | - | -207.19% | -124.79% |
Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
Interest Coverage | -31.69x | - | - | - | - | -2.11x | - | - | - | - |
FCF Conversion | 0.55x | 0.85x | 1.01x | 0.90x | 1.01x | 2.14x | 0.91x | 0.77x | 0.63x | 0.62x |
Related:ATXI Dividend History·ATXI Revenue History·ATXI Price History·ATXI P/E History·ATXI Financial Ratios·ATXI Institutional Holders
ATXI SEC Filings & Documents
Avenue Therapeutics, Inc. (ATXI) SEC filings — annual & quarterly reports (10-K, 10-Q)
ATXI Frequently Asked Questions
Avenue Therapeutics, Inc. (ATXI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Avenue Therapeutics, Inc. (ATXI) reported $1.4M in revenue for fiscal year 2025.
Avenue Therapeutics, Inc. (ATXI) grew revenue by 0.0% over the past year. Growth has been modest.
Avenue Therapeutics, Inc. (ATXI) reported a net loss of $1.8M for fiscal year 2025.
Dividend & Returns
Avenue Therapeutics, Inc. (ATXI) has a return on equity (ROE) of -157.8%. Negative ROE indicates the company is unprofitable.
Avenue Therapeutics, Inc. (ATXI) had negative free cash flow of $1.1M in fiscal year 2025, likely due to heavy capital investments.